LEBANON, N.H.--(BUSINESS WIRE)--Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced that 12 new partner programs entered clinical development in 2018. This brings the total number of Adimab partner programs that have entered the clinic to 21.
“We carefully track the progression of our partners’ programs and try to benchmark their success against established industry metrics. At this point we are seeing more than half of our funded discovery programs proceed into product development, which is well above industry average,” said Guy Van Meter, Senior Vice President of Business Development.
“It’s one thing to show fancy slides with fantasy data; it’s a very different thing to get actual molecules into clinical development. This year we more than doubled the number of Adimab antibodies in clinical development and saw the approval of our first antibody,” said Tillman Gerngross, Chief Executive Officer and Co-Founder of Adimab.
Resulting from a 2013 discovery collaboration, Innovent Biologics received BLA approval for its PD1 program in 2018, making it the most advanced partner program coming from the Adimab Platform. Notably, Innovent was able to go from discovery to BLA approval in five years.
Partners that have initiated clinical development in 2018 include Alector, Five Prime Therapeutics, Innovent Biologics, Merck, Novartis, Potenza Therapeutics (an Astellas Pharma company), Tizona Therapeutics, and others. In 2018, Adimab partners exercised options to 16 commercial licenses to advance programs into product development, bringing the total number of optioned programs to over 50. Partners exercising commercial options in 2018 include Alector, DragonFly Therapeutics, iTeos Therapeutics, Innovent Biologics, Regeneron, Takeda, Tusk Therapeutics, and others.
Adimab is the leading technology provider for antibody-based drug discovery, focusing solely on its partners without pursuing an internal product pipeline. Since 2009, Adimab has partnered with over 60 pharmaceutical and biotechnology companies. The Adimab technology has been transferred and implemented at Biogen, GSK, Lilly, Merck, and Novo Nordisk. Funded discovery partners include leading pharmaceutical companies, such as Boehringer Ingelheim, Celgene, Genentech, Gilead, Kyowa Hakko Kirin, Novartis, Roche, Sanofi, Takeda and others. Adimab has also partnered with many early-stage venture-backed companies, including Alector, Cullinan Oncology, Dragonfly, Pliant, Potenza, Tizona, iTeos and others, as well as mid-size public biopharmaceutical companies such as Acceleron, Five Prime, Innovent, Jounce, Mersana, Scholar Rock, Surface Oncology, and others.
Adimab’s integrated antibody discovery and engineering platform provides unprecedented speed from antigen to purified, full-length human IgGs. Adimab offers fundamental advantages by delivering diverse panels of therapeutically relevant antibodies that meet the most aggressive standards for affinity, epitope coverage, species cross-reactivity, and developability. Adimab enables its partners to rapidly expand their biologics pipelines through a broad spectrum of technology access arrangements. For more information, visit http://www.adimab.com.